<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744067</url>
  </required_header>
  <id_info>
    <org_study_id>2012/1419</org_study_id>
    <secondary_id>2012-004992-37</secondary_id>
    <secondary_id>2012033</secondary_id>
    <secondary_id>2012/1419</secondary_id>
    <nct_id>NCT01744067</nct_id>
  </id_info>
  <brief_title>The Effects of Omega-3 Fatty Acids in Renal Transplantation</brief_title>
  <acronym>ORENTRA</acronym>
  <official_title>The Effects of n-3 Polyunsaturated Fatty Acids on Renal and Cardiovascular Risk Markers in Renal Transplant Recipients: a Randomized Double Blinded Placebo Controlled Intervention Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pronova BioPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>South-Eastern Norway Regional Health Authority</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg Universitetshospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Omega-3 fatty acids are provided through dietary intake of fish and seafood. Several dietary
      supplements containing omega-3 fatty acids are also commercially available. Some studies have
      described beneficial effects from omega-3 fatty acids, among them are anti-inflammatory,
      anti-thrombotic, anti-atherosclerotic, anti-arrhythmic, anti-hypertensive and
      lipid-modulating effects. Other studies have not confirmed these findings. This study will
      investigate the effects of omega-3 fatty acids on renal function and cardiovascular risk
      markers in renal transplant recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There have been few interventional studies regarding the clinical effect of omega-3 fatty
      acids in renal transplantation. The aim of this study is to investigate the effects of
      omega-3 fatty acids on renal function and cardiovascular risk markers in renal transplant
      recipients.

      This study is a randomized double blinded placebo controlled interventional study of 132
      Norwegian renal transplant recipients. It will investigate, on the one hand, the effect of
      omega-3 fatty acids on renal function and, on the other, the effect of omega-3 fatty acids on
      cardiovascular risk markers in renal transplant recipients.

      8 weeks after transplantation, if renal function has stabilized, patients with a eGFR&gt;30 will
      be randomized to receive either 2,7 g eicosapentaenoic plus docosahexaenoic acid (3 capsules
      of Omacor a 1 g) daily or placebo. Baseline measurements will be performed before they start
      taking the study medication. The same measurements will performed again1 year after
      transplantation and the patients stops taking the study medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glomerular filtration rate</measure>
    <time_frame>44 weeks</time_frame>
    <description>Iohexol clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>44 weeks</time_frame>
    <description>Both ACR and FEPR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation in the renal transplant</measure>
    <time_frame>44 weeks</time_frame>
    <description>Degree of total inflammation in renal transplant biopsies, scores by PI and rescored by two pathologists.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis in the renal transplant</measure>
    <time_frame>44 weeks</time_frame>
    <description>As for inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>44 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability</measure>
    <time_frame>44 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow mediated dilation</measure>
    <time_frame>44 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity and augmentation index</measure>
    <time_frame>44 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose</measure>
    <time_frame>44 weeks</time_frame>
    <description>HbA1c and oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids</measure>
    <time_frame>44 weeks</time_frame>
    <description>Total, LDL and HDL cholesterol, triglycerid and ratios</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>44 weeks</time_frame>
    <description>Visceral fat volume and weight, visceral to subcutaneous fat ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>44 weeks</time_frame>
    <description>Regular BMD in the lumbar spine, hips, femur and arms and also selected to trabecular bone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body mass index</measure>
    <time_frame>44 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D levels</measure>
    <time_frame>44 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty acid composition in plasma and renal tissue</measure>
    <time_frame>44 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tacrolimus pharmacokinetics</measure>
    <time_frame>12 weeks</time_frame>
    <description>Substudy of 15 patients, where we study tacrolimus trough levels, Tmax and AUC at the end of the ORENTRA trial, after a minimum of 4 weeks wash-out and again after 4 weeks of 2.7 g omega-3 fatty acid supplementation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of post-transplant complications</measure>
    <time_frame>44 weeks + 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>44 weeks + 8 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>44 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of clinically significant safety laboratory variables</measure>
    <time_frame>44 weeks</time_frame>
    <description>Especially INR and tacrolimus trough concentrations. Follow-up by local nephrologist plus five Telephone Controls during follow-up.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>44 weeks</time_frame>
    <description>The participants fill out SF-36 at baseline and the 1 year post transplant control for both safety reasons and measurement of differences between the groups with regards to quality of life.</description>
  </other_outcome>
  <other_outcome>
    <measure>Food questionnaire</measure>
    <time_frame>44 weeks</time_frame>
    <description>Two specially designed food questionnaires to obtain data on dietary habits in general and type and amount of fish consumed</description>
  </other_outcome>
  <other_outcome>
    <measure>Comorbidity, concomitant medication and life-style factor interview</measure>
    <time_frame>44 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Disorder Related to Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>Omega-3 fatty acids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2,7 g omega-3 fatty acids / day: Omacor 1 g 1 capsule by mouth 3 times a day for 44 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: 1 capsule containing 1 g of olive oil by mouth 3 times a day for 44 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fatty acids</intervention_name>
    <description>2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)</description>
    <arm_group_label>Omega-3 fatty acids</arm_group_label>
    <other_name>Omacor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules 3 times a day (oral administration)</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Olive oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over the age of 18 who have received a kidney transplant. Patients with a
             functioning kidney transplant, defined as eGFR&gt;30 ml/min. Signed informed consent.

        Exclusion Criteria:

          -  Patients participating in clinical trials with other investigational drugs. Patients
             who received a deceased donor kidney from a donor &gt;75 years. Patients with a history
             of an allergic reaction or significant sensitivity to the study drug or drugs similar
             to the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivar A Eide, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <state>* Other</state>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0027</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <last_update_submitted>December 6, 2015</last_update_submitted>
  <last_update_submitted_qc>December 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Ivar Eide</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Renal transplantation</keyword>
  <keyword>Interventional study</keyword>
  <keyword>Glomerular filtration rate</keyword>
  <keyword>Renal function</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Cardiovascular risk markers</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Flow mediated vasodilation</keyword>
  <keyword>Heart rate variability</keyword>
  <keyword>Pulse wave velocity</keyword>
  <keyword>Lipids</keyword>
  <keyword>Blood glucose</keyword>
  <keyword>Bone mineral density</keyword>
  <keyword>Body composition</keyword>
  <keyword>Fat distribution</keyword>
  <keyword>Body mass index</keyword>
  <keyword>Fatty acid composition</keyword>
  <keyword>Tacrolimus pharmacokinetics</keyword>
  <keyword>Omega-3 fatty acids</keyword>
  <keyword>Marine n-3 fatty acids</keyword>
  <keyword>Fatty acids</keyword>
  <keyword>Gas chromatography</keyword>
  <keyword>Interstitial fibrosis</keyword>
  <keyword>Inflammation</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

